晚期前列腺癌:AUA/ASTRO/SUO指南第二部分
本文为AUA/ASTRO/SUO晚期前列腺癌指南第二部分,聚焦去势抵抗性疾病的预后与治疗推荐。专家组基于系统综述与共识制定循证指南陈述,以协助临床管理。指南旨在提升临床医生治疗晚期前列腺癌患者的能力。
要点
- 本部分针对去势抵抗性前列腺癌的预后与治疗给出推荐。
- 指南陈述基于系统综述与共识制定,详见原文图1。
- 生化复发无转移及转移性激素敏感阶段见第一部分。
核心结论
- 指南旨在改善临床医生对晚期前列腺癌患者的治疗能力。
- 未来高质量试验证据的持续发表对提升此类患者照护水平至关重要。
研究设计与样本
- 由独立方法学顾问开展系统综述以支持指南制定。
- 发表前更新检索至2020年1月20日。
- 方法学团队补充检索了既往AUA综述纳入的研究及相关文章参考文献列表。
主要发现
- 晚期前列腺癌专家组制定了基于证据与共识的指南陈述,以协助管理晚期前列腺癌患者。
- 指南陈述汇总于原文图1并在正文中详述。
临床怎么用
- 临床医生可依据本指南第二部分管理去势抵抗性前列腺癌患者的预后与治疗。
- 生化复发无转移及转移性激素敏感患者的管理请参阅指南第一部分。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The summary presented herein represents Part II of the two-part series dedicated to Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline discussing prognostic and treatment recommendations for patients with castration-resistant disease. Please refer to Part I for discussion of the management of patients with biochemical recurrence without metastatic disease after exhaustion of local treatment options as well as those with metastatic hormone-sensitive prostate cancer. RESULTS: The Advanced Prostate Cancer Panel created evidence- and consensus-based guideline statements to aid clinicians in the management of patients with advanced prostate cancer. Such statements are summarized in figure 1[Figure: see text] and detailed herein. MATERIALS AND METHODS: The systematic review utilized to inform this guideline was conducted by an independent methodological consultant. A research librarian conducted searches in Ovid MEDLINE (1998 to January Week 5 2019), Cochrane Central Register of Controlled Trials (through December 2018), and Cochrane Database of Systematic Reviews (2005 through February 6, 2019). An updated search was conducted prior to publication through January 20, 2020. The methodology team supplemented searches of electronic databases with the studies included in the prior AUA review and by reviewing reference lists of relevant articles. CONCLUSIONS: This guideline attempts to improve a clinician's ability to treat patients diagnosed with advanced prostate cancer. Continued research and publication of high-quality evidence from future trials will be essential to improve the level of care for these patients.
引用
- Lowrance WT, Breau RH, Chou R, et al. Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART II. J Urol. 2020. PMID: 32960678. doi:10.1097/JU.0000000000001376
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。